IMI plans "unprecedented" programme for novel antibiotics as drug resistance continues to rise
This article was originally published in Scrip
The EU's Innovative Medicines Initiative (IMI) is to launch a new collaborative programme in the next few months aimed at boosting the discovery and development of novel antimicrobial medicines, as pressure grow for more action to tackle the problem of bacterial resistance.
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.